Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
BPC157, also known as Body Protection Compound 157 hinting at it therapeutic potential, is synthetic peptide based off of naturally occurring peptides secreted by the gut
Alphaderm 137
Regulatory and compounding status All four compounds share a broadly similar regulatory landscape in the United States as of 2026: None are FDA-approved as finished drug products for therapeutic use All are classified as WADA S2 prohibited substances year-round All four have 503A compounding status of Under Review, meaning the FDA Pharmacy Compounding Advisory Committee (PCAC) has nominated them for evaluation but final category assignments (Category 1 permitted for compounding
The realistic timeline Based on the current state of the clinical program, regulatory precedent, and publicly available information from Eli Lilly, here is the most realistic projection: Mid to late 2026: Remaining TRIUMPH, TRANSCEND, and SYNERGY Phase 3 results are reported
Durham Peptides supplies 10mL
The acetylated polyamines can be exported from cells via heteromeric transporters containing the SLC3A2 encoded heavy chain subunit
US$ 26.13
US$ 23.16
US$ 24.20
US$ 26.72
